Today in Medmultilingua
Pancreatic cancer remains one of the deadliest malignancies: silent, hard to detect, and resistant to conventional therapies. Icons such as Steve Jobs, Patrick Swayze, and David Bowie remind us of its devastating impact.
In this context, the U.S. FDA has approved daraxonrasib (Rasonque), a breakthrough targeted therapy. Unlike chemotherapy, daraxonrasib blocks the KRAS protein—a genetic driver that keeps cancer cells growing uncontrollably. Administered as two pills a day, it offers a simpler regimen with remarkable results.
In a phase 3 trial with 500 patients suffering metastatic pancreatic cancer, survival nearly doubled: 13.2 months with daraxonrasib versus 6.6 months with chemotherapy. Some patients lived for years, an outcome rarely seen in this disease.
This milestone not only brings real hope to pancreatic cancer patients but also opens the door to KRAS-targeted therapies in other cancers such as lung and colon. While cost and global access remain uncertain, the approval signals a paradigm shift toward precision medicine—transforming genetic insights into longer lives and renewed hope.
